prikaz prve stranice dokumenta Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
  Download
PDF 944.07 KB
Scientific paper - Original scientific paper
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
Arthritis & Rheumatology, 71 (2019), 9; 1553-1570. https://doi.org/10.1002/art.40906
(EUSTAR Collaboration) Sobanski, Vincent; Giovannelli, Jonathan; ...; Novak, Srđan; ...; Martinović, Duška; ...; Morović- Vergles, Jadranka; ...; Anić, Branimir; Barešić, Marko; Mayer, Miroslav; ...; ...

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Sobanski, V., Giovannelli, J., Novak, S., Martinović, D., Morović Vergles, J., Anić, B. ... Mayer, M. (2019). Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis & Rheumatology, 71. (9), 1553-1570. doi: 10.1002/art.40906

Sobanski, Vincent, et al. "Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis." Arthritis & Rheumatology, vol. 71, no. 9, 2019, pp. 1553-1570. https://doi.org/10.1002/art.40906

Sobanski, Vincent, Jonathan Giovannelli, Srđan Novak, Duška Martinović, Jadranka Morović Vergles, Branimir Anić, Marko Barešić and Miroslav Mayer. "Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis." Arthritis & Rheumatology 71, no. 9 (2019): 1553-1570. https://doi.org/10.1002/art.40906

Sobanski, V., et al. (2019) 'Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis', Arthritis & Rheumatology, 71(9), pp. 1553-1570. doi: 10.1002/art.40906

Sobanski V, Giovannelli J, Novak S, Martinović D, Morović Vergles J, Anić B, and sur.. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis & Rheumatology [Internet]. 2019 [cited 2024 May 06];71(9):1553-1570. doi: 10.1002/art.40906

V. Sobanski, et al., "Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis", Arthritis & Rheumatology, vol. 71, no. 9, pp. 1553-1570, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:759959. [Accessed: 06 May 2024]

Metadata
Title (english)Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
AuthorVincent Sobanski
AuthorJonathan Giovannelli
Author
...
AuthorSrđan Novak
Author
...
AuthorDuška Martinović
Author
...
AuthorJadranka Morović- Vergles
MBZ: 140933
Author
...
AuthorBranimir Anić
MBZ: 140514
AuthorMarko Barešić
MBZ: 224326
AuthorMiroslav Mayer
MBZ: 383474
Author
...
Author
...
CollaborationEUSTAR Collaboration
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
OBJECTIVE: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease that is typically subdivided into limited cutaneous SSc (lcSSc) and diffuse cutaneous SSc (dcSSc) depending on the extent of skin involvement. This subclassification may not capture the entire variability of clinical phenotypes. The European Scleroderma Trials and Research (EUSTAR) database includes data on a prospective cohort of SSc patients from 122 European referral centers. This study was undertaken to perform a cluster analysis of EUSTAR data to distinguish and characterize homogeneous phenotypes without any a priori assumptions, and to examine survival among the clusters obtained. METHODS: A total of 11, 318 patients were registered in the EUSTAR database, and 6, 927 were included in the study. Twenty-four clinical and serologic variables were used for clustering. RESULTS: Clustering analyses provided a first delineation of 2 clusters showing moderate stability. In an exploratory attempt, we further characterized 6 homogeneous groups that differed with regard to their clinical features, autoantibody profile, and mortality. Some groups resembled usual dcSSc or lcSSc prototypes, but others exhibited unique features, such as a majority of lcSSc patients with a high rate of visceral damage and antitopoisomerase antibodies. Prognosis varied among groups and the presence of organ damage markedly impacted survival regardless of cutaneous involvement. CONCLUSION: Our findings suggest that restricting subsets of SSc patients to only those based on cutaneous involvement may not capture the complete heterogeneity of the disease. Organ damage and antibody profile should be taken into consideration when individuating homogeneous groups of patients with a distinct prognosis
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleArthritis & Rheumatology
Numberingvol. 71, no. 9, pp. 1553-1570
p-ISSN2326-5191
DOIhttps://doi.org/10.1002/art.40906
URN:NBNurn:nbn:hr:184:759959
Publication2019
Document URLhttp://bib.irb.hr/1030428
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) icon
Created on2022-03-02 14:12:52